This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vongpatanasin, W. Articles by Jialal, I. Search for Related Content PubMed PubMed Citation Articles by Vongpatanasin, W. Articles by Jialal, I.

Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women

Wanpen Vongpatanasin, MD, FACC^*,*, Meryem Tuncel, MD^*, Zhongyun Wang, MD^*, Debbie Arbique, RN^*, Borna Mehrad, MD^* and Ishwarlal Jialal, MD, PhD

^* Donald W. Reynolds Cardiovascular Clinical Research Center, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA
Laboratory for Atherosclerosis and Metabolic Research, Department of Pathology, University of California at Davis Medical Center, Sacramento, California, USA

View larger version (25K): [in a new window]   Figure 1 Individual and summary data of all subjects showing C-reactive protein (CRP) levels before and after oral estrogen (left panel), placebo (middle panel), and transdermal estrogen (right panel). Transdermal estrogen had no effect on CRP. Oral estrogen administration for eight weeks evoked a more than twofold increase in CRP (*p < 0.01 vs. baseline, placebo, and transdermal estrogen).

View larger version (15K): [in a new window]   Figure 2 Scatter plots showing the inverse correlation between changes in serum insulin-like growth factor-1 (IGF-1) from baseline and changes in C-reactive protein (CRP) from baseline, regardless of the treatment each woman received.